These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
741 related articles for article (PubMed ID: 32750319)
21. Recent advances in the clinical development of immune checkpoint blockade therapy. Ghahremanloo A; Soltani A; Modaresi SMS; Hashemy SI Cell Oncol (Dordr); 2019 Oct; 42(5):609-626. PubMed ID: 31201647 [TBL] [Abstract][Full Text] [Related]
22. Recent Findings in the Regulation of Programmed Death Ligand 1 Expression. Shen X; Zhang L; Li J; Li Y; Wang Y; Xu ZX Front Immunol; 2019; 10():1337. PubMed ID: 31258527 [TBL] [Abstract][Full Text] [Related]
23. Immunotherapy and predictive immunologic profile: the tip of the iceberg. Cunha Pereira T; Rodrigues-Santos P; Almeida JS; RĂªgo Salgueiro F; Monteiro AR; Macedo F; Soares RF; Domingues I; Jacinto P; Sousa G Med Oncol; 2021 Mar; 38(5):51. PubMed ID: 33788049 [TBL] [Abstract][Full Text] [Related]
24. Checkpoint inhibitors in AML: are we there yet? Ghosh A; Barba P; Perales MA Br J Haematol; 2020 Jan; 188(1):159-167. PubMed ID: 31808941 [TBL] [Abstract][Full Text] [Related]
28. Immune-Checkpoint Blockade Therapy in Lymphoma. Kuzume A; Chi S; Yamauchi N; Minami Y Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32751706 [TBL] [Abstract][Full Text] [Related]
29. PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations. Jiang Y; Chen M; Nie H; Yuan Y Hum Vaccin Immunother; 2019; 15(5):1111-1122. PubMed ID: 30888929 [TBL] [Abstract][Full Text] [Related]
30. Development of small-molecule immune checkpoint inhibitors of PD-1/PD-L1 as a new therapeutic strategy for tumour immunotherapy. Li K; Tian H J Drug Target; 2019 Mar; 27(3):244-256. PubMed ID: 29448849 [TBL] [Abstract][Full Text] [Related]
31. [The "immune checkpoints", how does it work]. Granier C; Soumelis V; Mandavit M; Gibault L; Belazzoug R; de Guillebon E; Badoual C; Tartour E; Roussel H Ann Pathol; 2017 Feb; 37(1):18-28. PubMed ID: 28160999 [TBL] [Abstract][Full Text] [Related]
32. Editorial: Immune Checkpoint Molecules and Cancer Immunotherapy. Bazhin AV; Amedei A; Karakhanova S Front Immunol; 2018; 9():2878. PubMed ID: 30568661 [No Abstract] [Full Text] [Related]
33. Immunopathogenesis of Immune Checkpoint Inhibitor-Related Adverse Events: Roles of the Intestinal Microbiome and Th17 Cells. Anderson R; Theron AJ; Rapoport BL Front Immunol; 2019; 10():2254. PubMed ID: 31616428 [TBL] [Abstract][Full Text] [Related]
34. Novel Small Molecule Inhibitors of Programmed Cell Death (PD)-1, and its Ligand, PD-L1 in Cancer Immunotherapy: A Review Update of Patent Literature. Kopalli SR; Kang TB; Lee KH; Koppula S Recent Pat Anticancer Drug Discov; 2019; 14(2):100-112. PubMed ID: 30370857 [TBL] [Abstract][Full Text] [Related]
35. Immune Checkpoint Inhibitors for Cancer Therapy: Clinical Efficacy and Safety. Azoury SC; Straughan DM; Shukla V Curr Cancer Drug Targets; 2015; 15(6):452-62. PubMed ID: 26282545 [TBL] [Abstract][Full Text] [Related]
36. Coinhibitory Pathways in Immunotherapy for Cancer. Baumeister SH; Freeman GJ; Dranoff G; Sharpe AH Annu Rev Immunol; 2016 May; 34():539-73. PubMed ID: 26927206 [TBL] [Abstract][Full Text] [Related]
37. Predicting immunotherapy response through genomics. Cormedi MCV; Van Allen EM; Colli LM Curr Opin Genet Dev; 2021 Feb; 66():1-9. PubMed ID: 33307238 [TBL] [Abstract][Full Text] [Related]